Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

dc.contributor.authorClèries Soler, Ramon
dc.contributor.authorAmeijide, Alberto
dc.contributor.authorBuxó, Maria
dc.contributor.authorVilardell, Mireia
dc.contributor.authorMartínez, José Miguel
dc.contributor.authorFont, Rebeca
dc.contributor.authorMarcos Gragera, Rafael
dc.contributor.authorPuigdemont, Montse
dc.contributor.authorViñas, Gemma
dc.contributor.authorCarulla, Marià
dc.contributor.authorEspinàs Piñol, Josep Alfons
dc.contributor.authorGalceran, Jaume
dc.contributor.authorIzquierdo, Ángel
dc.contributor.authorBorràs Andrés, Josep Maria
dc.date.accessioned2023-02-06T09:37:15Z
dc.date.available2023-02-06T09:37:15Z
dc.date.issued2022-12-27
dc.date.updated2023-02-02T10:27:39Z
dc.description.abstractMortality from cardiovascular disease (CVD), second tumours, and other causes is of clinical interest in the long-term follow-up of breast cancer (BC) patients. Using a cohort of BC patients (N = 6758) from the cancer registries of Girona and Tarragona (north-eastern Spain), we studied the 10-year probabilities of death due to BC, other cancers, and CVD according to stage at diagnosis and hormone receptor (HR) status. Among the non-BC causes of death (N = 720), CVD (N = 218) surpassed other cancers (N = 196). The BC cohort presented a significantly higher risk of death due to endometrial and ovarian cancers than the general population. In Stage I, HR- patients showed a 1.72-fold higher probability of all-cause death and a 6.11-fold higher probability of breast cancer death than HR+ patients. In Stages II-III, the probability of CVD death (range 3.11% to 3.86%) surpassed that of other cancers (range 0.54% to 3.11%). In Stage IV patients, the probability of death from any cancer drove the mortality risk. Promoting screening and preventive measures in BC patients are warranted, since long-term control should encompass early detection of second neoplasms, ruling out the possibility of late recurrence. In patients diagnosed in Stages II-III at an older age, surveillance for preventing late cardiotoxicity is crucial.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1660-4601
dc.identifier.urihttps://hdl.handle.net/2445/193134
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph20010405
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2022, vol. 20, num. 1, p. 405
dc.relation.urihttps://doi.org/10.3390/ijerph20010405
dc.rightscc by (c) Clèries Soler, Ramon et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationCàncer de mama
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationMortalitat
dc.subject.otherBreast cancer
dc.subject.otherCardiovascular diseases
dc.subject.otherMortality
dc.titleTen-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
ijerph-20-00405.pdf
Mida:
4.47 MB
Format:
Adobe Portable Document Format